Investornewsbreaks TC Biopharm Holdings PLC (NASDAQ: TCBP) Advances Preclinical Studies For Bird Flu Treatment With TCB008

(MENAFN- Investor Brand Network) TC BioPharm (NASDAQ: TCBP) , a clinical-stage biotech company, announced plans to initiate Proof of Concept preclinical studies for its lead therapy, TCB008, targeting H5N1“bird flu.” TCB008 is an allogeneic gamma delta T cell therapy designed to leverage the immune system against infections like H5N1, which recently caused the first reported U.S. fatality in Louisiana. TC BioPharm aims to collaborate with leading infectious disease centers or universities to expedite studies and prepare for a Phase I trial. CEO Bryan Kobel emphasized TCB008's potential in addressing infectious diseases, underscoring the company's commitment to combating emerging health threats.

To view the full press release, visit:

About TC BioPharm Holdings PLC

TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line – Phase 2b/3 pivotal trial for OmnImmune(R) in treatment of acute myeloid leukemia using the company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. For more information about the company, visit
.

NOTE TO INVESTORS:
The latest news and updates relating to TCBP are available in the company's newsroom at

About InvestorWire

InvestorWire
(“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:
/Disclaimer

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by
IBN

MENAFN15012025000224011066ID1109094666